Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.24+0.03 (+11.89%)
Close on Nov 18, 2026Market cap $568.73KP/E –Yield –
Lakewood-Amedex Biotherapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.47M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$923.29K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$655.94K | – |
| Q1 FY2025 | Mar 31, 2025 | -$539.62K | – |
See a number that looks wrong?